Online inquiry

IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15391MR)

This product GTTS-WQ15391MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ15391MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11591MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ154MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ6920MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ8652MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ14365MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ13412MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ13036MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ2818MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW